Lymphoma Research: 10 LLS Grants You Should Know
3. Screen to Lead Program
The Screen to Lead Program is now closed, but the LLS is planning on opening applications for the program again in July 2016. The grant will be awarded to qualified academic laboratories to be invested in drug discovery research, specifically focused on medicinal chemistry and/or drug target screening in hematological malignancies. The applications will be peer reviewed by a special committee to be launched in July 2017 and are anticipated to be for two years.
Find out more here.
4. Translational Research Program
The Translational Research Program supports research projects focused on decreasing the time between laboratory findings and actual treatment. With a maximum of $200,000, the grant is attributed to new and innovative projects that demonstrate high promise for translating basic biomedical knowledge to clinical application, and it aims to fast-track the development of more effective treatments and a cure for leukemia, lymphoma, and myeloma. The application process for the Translational Research Program is currently closed since applications are under review.
Find out more here.
5. RTFCCR/LLS Patient-Focused ImmunotherapyResearch Grant for Blood Cancer
The RTFCCR/LLS Patient-Focused ImmunotherapyResearch Grant for Blood Cancer is a partnership of LLS and the Swiss private foundation Rising Tide Foundation for Clinical Cancer Research (RTFCCR). It is focused on stimulating innovative and clinically relevant cancer research that has the highest potential for near-term patient impact in terms of clinical application, therapeutic outcomes and quality of life. The application process for RTFCCR/LLS Patient-Focused ImmunotherapyResearch Grant for Blood Cancer are closed, and the results of applications currently under review will be announced next October.
Find out more here.
